Biologic therapies targeting IL-6 and IL-1 have also been reported as being in use for cytokine storm, but the lack of evidence and randomized control trial data on their efficacy in the management of MIS-A means that the therapy is based on the expertise and protocols for Kawasaki disease (KD). Here, IL1A is linked to Kawasaki disease.